Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 24, 2024

BUY
$1.59 - $3.85 $5,727 - $13,867
3,602 Added 14.88%
27,802 $92,000
Q3 2023

Nov 06, 2023

BUY
$3.74 - $5.45 $3,227 - $4,703
863 Added 3.7%
24,200 $90,000
Q2 2023

Aug 01, 2023

BUY
$3.79 - $8.3 $20,117 - $44,056
5,308 Added 29.44%
23,337 $99,000
Q1 2023

Apr 27, 2023

BUY
$5.89 - $10.52 $2,850 - $5,091
484 Added 2.76%
18,029 $123,000
Q4 2022

Feb 07, 2023

BUY
$5.69 - $10.07 $4,056 - $7,179
713 Added 4.24%
17,545 $138,000
Q3 2022

Nov 07, 2022

BUY
$7.17 - $13.87 $566 - $1,095
79 Added 0.47%
16,832 $162,000
Q2 2022

Jul 28, 2022

BUY
$5.86 - $13.23 $867 - $1,958
148 Added 0.89%
16,753 $121,000
Q1 2022

May 04, 2022

BUY
$10.92 - $16.41 $1,506 - $2,264
138 Added 0.84%
16,605 $214,000
Q4 2021

Feb 04, 2022

SELL
$15.81 - $18.99 $632 - $759
-40 Reduced 0.24%
16,467 $263,000
Q3 2021

Nov 12, 2021

BUY
$12.68 - $17.79 $8,584 - $12,043
677 Added 4.28%
16,507 $265,000
Q2 2021

Aug 02, 2021

SELL
$12.95 - $15.41 $12,289 - $14,624
-949 Reduced 5.66%
15,830 $219,000
Q1 2021

May 06, 2021

BUY
$14.42 - $21.39 $2,840 - $4,213
197 Added 1.19%
16,779 $245,000
Q4 2020

Jan 28, 2021

SELL
$16.56 - $18.94 $8,876 - $10,151
-536 Reduced 3.13%
16,582 $288,000
Q3 2020

Nov 05, 2020

BUY
$17.41 - $19.89 $77,561 - $88,609
4,455 Added 35.18%
17,118 $314,000
Q2 2020

Aug 04, 2020

BUY
$14.43 - $19.16 $4,545 - $6,035
315 Added 2.55%
12,663 $226,000
Q1 2020

May 05, 2020

BUY
$11.67 - $22.53 $144,101 - $278,200
12,348 New
12,348 $200,000

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $115M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Arizona State Retirement System Portfolio

Follow Arizona State Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arizona State Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on Arizona State Retirement System with notifications on news.